Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

FGF-1 affixation stimulates ePTFE endothelialization without intimal hyperplasia

J L Gray1, S S Kang, G C Zenni

  • 1Department of Surgery, Loyola University Medical Center, Maywood, IL 60153.

The Journal of Surgical Research
|November 1, 1994
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aphasia: A Clinical Lecture by Professor J. A. Robison, Delivered at Cook County Hospital.

The Chicago medical journal and examiner·2023
Same author

Hemocytic sarcoma of the body wall in a California king crab Paralithodes californiensis.

Diseases of aquatic organisms·2021
Same author

Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomes.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics.

Oncogene·2015

Fibroblast growth factor (FGF)-1 affixation to vascular grafts enhanced capillary ingrowth and endothelialization. This FGF-1 treatment promoted graft healing without significant intimal hyperplasia in a canine model.

Area of Science:

  • Biomaterials Science
  • Regenerative Medicine
  • Vascular Surgery

Background:

  • Porous vascular grafts are used to replace damaged vessels.
  • Fibroblast growth factor (FGF)-1 has shown potential in promoting vascular healing.
  • Previous studies suggest FGF-1 can stimulate capillary ingrowth and endothelialization.

Purpose of the Study:

  • To further characterize the effects of FGF-1 affixation to expanded polytetrafluoroethylene (ePTFE) vascular grafts.
  • To evaluate graft healing and cellular responses over 140 days in a canine model.
  • To assess capillarization, endothelialization, and intimal hyperplasia in FGF-1 treated grafts.

Main Methods:

  • ePTFE grafts were impregnated with FGF-1 and heparin in fibrin glue (FG) or FG with heparin alone (controls).

Related Experiment Videos

  • Grafts were implanted in canine aortas and explanted at 10, 30, and 140 days.
  • Analyses included microscopy, immunohistochemistry, morphometry, autoradiography, RT-PCR, and hydroxyproline colorimetry.

    • Main Results:

    • FGF-1 treated grafts showed significantly increased capillarization and luminal endothelialization (86.7% at 140 days) compared to controls (46.1-48.1%).
    • Inner capsule thickness was greater in FGF-1 grafts (138.8 microns) versus controls (93-67 microns) at 140 days.
    • FGF-1 induced a transient increase in mitotic activity of myofibroblasts and endothelial cells at 30 days, returning to baseline by 140 days. No significant intimal hyperplasia was observed.

    Conclusions:

    • FGF-1 affixation to ePTFE grafts promotes significant capillarization and surface endothelialization.
    • The treatment leads to enhanced graft healing and tissue integration without detrimental intimal hyperplasia.
    • FGF-1 may be a valuable therapeutic agent for improving vascular graft performance.